Drug Trial Radar · NCT05620017
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Nov 30, 2022
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
Conditions
- Advanced Solid Tumors
Interventions
BAT8008 for InjectionDrug
Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: At the end of Cycle 1( first cycle is 21 days, subsequent cycles are 14 days)
- Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1( first cycle is 21 days, subsequent cycles are 14 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.